Milestone Pharmaceuticals (NASDAQ:MIST) Given Buy Rating at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Milestone Pharmaceuticals (NASDAQ:MIST) in a research note published on Monday morning,Benzinga reports. The brokerage currently has a $25.00 target price on the stock.

Milestone Pharmaceuticals Stock Up 11.1 %

Shares of NASDAQ:MIST opened at $2.41 on Monday. Milestone Pharmaceuticals has a 12 month low of $1.12 and a 12 month high of $2.75. The company’s 50-day moving average price is $2.02 and its two-hundred day moving average price is $1.81. The company has a quick ratio of 15.40, a current ratio of 15.40 and a debt-to-equity ratio of 2.18. The firm has a market cap of $128.52 million, a P/E ratio of -2.98 and a beta of 1.83.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the business. Toronto Dominion Bank acquired a new position in Milestone Pharmaceuticals during the 4th quarter valued at about $1,770,000. Boxer Capital Management LLC acquired a new position in Milestone Pharmaceuticals during the 4th quarter valued at about $729,000. Virtu Financial LLC acquired a new position in Milestone Pharmaceuticals during the 4th quarter valued at about $170,000. Northern Trust Corp lifted its position in Milestone Pharmaceuticals by 112.6% during the 4th quarter. Northern Trust Corp now owns 58,108 shares of the company’s stock valued at $137,000 after purchasing an additional 30,772 shares during the period. Finally, Atria Investments Inc lifted its position in Milestone Pharmaceuticals by 44.4% during the 3rd quarter. Atria Investments Inc now owns 40,421 shares of the company’s stock valued at $61,000 after purchasing an additional 12,430 shares during the period. 86.18% of the stock is currently owned by institutional investors and hedge funds.

About Milestone Pharmaceuticals

Milestone Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate.